These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Cardiovascular consequences of renal anaemia and erythropoietin therapy. Eckardt KU Nephrol Dial Transplant; 1999 May; 14(5):1317-23. PubMed ID: 10344393 [TBL] [Abstract][Full Text] [Related]
7. [Cardiovascular complications in patients with chronic renal insufficiency and chronic kidney failure]. Tesar V Vnitr Lek; 2003 May; 49(5):383-7. PubMed ID: 12908173 [TBL] [Abstract][Full Text] [Related]
8. Should hemoglobin be normalized in uremic patients? Foley RN Clin Nephrol; 2002 Jul; 58 Suppl 1():S58-61. PubMed ID: 12227728 [TBL] [Abstract][Full Text] [Related]
9. Anaemia in chronic renal disease: lessons learned since Seville 1994. Parfrey P Nephrol Dial Transplant; 2001; 16 Suppl 7():41-5. PubMed ID: 11590256 [TBL] [Abstract][Full Text] [Related]
10. Anaemia and early phase cardiovascular events on haemodialysis. Hayashi T; Joki N; Tanaka Y; Hase H Nephrology (Carlton); 2015 Dec; 20 Suppl 4():1-6. PubMed ID: 26456311 [TBL] [Abstract][Full Text] [Related]
11. Haemoglobin and haematocrit targets for the anaemia of chronic renal disease. Strippoli GF; Manno C; Schena FP; Craig JC Cochrane Database Syst Rev; 2003; (1):CD003967. PubMed ID: 12535495 [TBL] [Abstract][Full Text] [Related]
12. Hemoglobin levels, cardiovascular disease, and left ventricular hypertrophy in patients with chronic kidney disease. Case study of the anemic patient. Butler KG Nephrol Nurs J; 2002 Apr; 29(2):189-92. PubMed ID: 11997954 [TBL] [Abstract][Full Text] [Related]
13. Prevalence of cardiovascular damage in early renal disease. Levin A Nephrol Dial Transplant; 2001; 16 Suppl 2():7-11. PubMed ID: 11369842 [TBL] [Abstract][Full Text] [Related]
14. The beneficial effects of intervention in early renal disease. Portolés J Nephrol Dial Transplant; 2001; 16 Suppl 2():12-5. PubMed ID: 11369843 [TBL] [Abstract][Full Text] [Related]
16. Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. Locatelli F; Aljama P; Canaud B; Covic A; De Francisco A; Macdougall IC; Wiecek A; Vanholder R; Nephrol Dial Transplant; 2010 Sep; 25(9):2846-50. PubMed ID: 20591813 [TBL] [Abstract][Full Text] [Related]
17. Anaemia management and cardiomyopathy in renal failure. Donne RL; Foley RN Nephrol Dial Transplant; 2002; 17 Suppl 1():37-40. PubMed ID: 11812910 [TBL] [Abstract][Full Text] [Related]
18. Pathophysiology of cardiovascular damage in the early renal population. London G Nephrol Dial Transplant; 2001; 16 Suppl 2():3-6. PubMed ID: 11369841 [TBL] [Abstract][Full Text] [Related]